Global Information
회사소개 | 문의 | 위시리스트

CNS Drug News

리서치사 Fitch Solutions, Inc.
발행정보 22 회/년 상품 코드 4626
페이지 정보 영문 24 Pages
가격
US $ 1,135 ₩ 1,391,000 PDF by E-mail (Single User License)


CNS Drug News CNS Drug News
발행정보 : 22 회/년 페이지 정보 : 영문 24 Pages

최근 고령화 사회에 따라 고령층 특유의 병인 알츠하이머병,파킨슨병,뇌졸증 등과 그 치료약 연구의 중심이 되는 CNS(중추 신경계)와 CNS 약품에 업계의 관심이 모아지고 있고 이러한 경향은 이후 25년간 더욱 증가할 것이라고 생각됩니다. Espicom Business Intelligence 사에서 발행되고 있는 본 뉴스레터는 CNS 약품과 제약 회사,각국의 CNS 약품시장에 관해 풍부하고 다각적인 정보를 게재해서 매월 전해 드립니다.

    매월 게재항목
    • 통합 신정보
    • 회의일람
    매월 선택되어 게재되는 항목
    • 신경변성 이상
    • 신경 안정제
    • 항우울제
    • 정신이상
    • 진통제
    • 약물 의존증 치료
    • 항암약
    • 구토, 현기증 치료약
    • 식생활 이상
    • 뇌혈관 이상
    • 국제회의 R&D요약
mys 02.03.14

BMI View: Biogen Idec is seeking to diversify beyond multiple sclerosis and looking to fuel its future neurology drug pipeline, which if successful, would help the company to sustain growth. This acquisition will give the company the basis for a pipeline in an area of significant unmet need, expanding it beyond a single mid-stage candidate. The company will continue to look to expand its pipeline through acquisitions and partnerships.

Table of Contents

  • Expanded Portfolio Will Help Biogen Idec Sustain Growth Neurodegenerative Disorders
  • Parkinson's Disease - Agreements
  • Neuropore/UCB Enter Worldwide Collaboration And Agreement
  • Genomic Data Partnerships Will Bolster Drug Development
  • Product Updates
  • FDA Approves AbbVie's Duopa For Motor Fluctuations In Advanced PD Patients
  • FDA Approves Rytary For PD
  • R&D
  • Phase II/III And III Trials Of Rasagiline For PD Start In Japan
  • Newron Initiates Phase II Study Of sNN0031 In PD
  • Alzheimer's Disease - Agreements
  • Investment In Alzheimer's R&D To Continue With Focus On Mild Disease
  • Adamas Receives USD30mn Milestone Payment From Actavis
  • Other Neurodegenerative Disorders - Agreements
  • Treeway/uniQure Collaborate To Develop Gene Therapy For ALS
  • Isis Earns Milestone For Advancing ISIS-SMNRx In Children With SMA
  • R&D
  • DSMB Recommends Continuation Of Masitinib Phase III Study In ALS
  • Newron Initiates Phase II Study Of sNN0029 In ALS Anxiolytics/Sleep Disorders
  • Product Updates
  • Mundipharma Receives Positive EC Decision On Targin For RLS Psychotic Disorders
  • Product Updates
  • Resubmitted Cariprazine Can Expect Slow Sales Growth
  • Neos Submits NDA For Methylphenidate XR-ODT For ADHD
  • New Fanapt Patent Listed In FDA's Orange Book
  • Sunovion Files Lurasidone Patent Infringement Lawsuits
  • R&D
  • Alkermes Reports Positive Results From ALKS 3831 Phase II Trial In Schizophrenia
  • Newron Reports NW-3509 Phase I Results; Phase II Study In Schizophrenia Planned Analgesics/Anaesthetics
  • Agreements
  • Acura Partners With Egalet To Commercialise Oxaydo
  • Product Updates
  • Actavis Challenges US Abstral Patents
  • FDA Accepts With Priority Review Pernix' Treximet sNDA For Use In Adolescents
  • R&D
  • First Of Three Sativex Phase III Cancer Pain Trials Misses Primary Endpoint
  • Trevena Initiates Second Phase IIb Study Of TRV130 For Acute Postoperative Pain Anti-Epileptics
  • Product Updates
  • FDA Accepts Aptiom sNDA For Review
  • R&D
  • Perampanel Phase III Trial Conducted In Asia Meets Primary Endpoint Drugs used in Nausea & Vertigo
  • Product Updates
  • Helsinn Reaches Palonosetron Settlement With Sandoz General Development News
  • R&D
  • FDA Grants ODD To Auspex' SD-809 For Tourette's Syndrome In Paediatric Population Corporate Activity
  • Nucynta Deal Will More Than Double Depomed's Annual Net Product Sales
  • Roche To Acquire Trophos
  • Otsuka Completes Avanir Acquisition
  • CoLucid Raises Funds For Oral Lasmiditan Phase III Programme In Migraine
  • Amorfix To Centralise Operations In South San Francisco/Focus On Neurodegenerative Disease
  • NeuroPhage Raises Funds To Advance NPT088 Into The Clinic Conference Listings
Back to Top
전화 문의
F A Q